MedPath

Tinlarebant

Generic Name
Tinlarebant
Drug Type
Small Molecule
Chemical Formula
C21H21F5N4O2
CAS Number
1821327-95-0
Unique Ingredient Identifier
63WI9S8P1M
Clinical Trials
Related News

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects with Stargardt Disease

Phase 2
Recruiting
Conditions
Stargardt Disease 1
STGD1
Interventions
Drug: Placebo
First Posted Date
2024-04-29
Last Posted Date
2025-02-14
Lead Sponsor
Belite Bio, Inc
Target Recruit Count
60
Registration Number
NCT06388083
Locations
🇯🇵

Belite Study Site, Tokyo, Japan

🇬🇧

Bellite Study Site, London, United Kingdom

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

Phase 3
Recruiting
Conditions
Geographic Atrophy
Interventions
Drug: Placebo
First Posted Date
2023-07-18
Last Posted Date
2025-02-14
Lead Sponsor
Belite Bio, Inc
Target Recruit Count
429
Registration Number
NCT05949593
Locations
🇬🇧

Belite Study Site, London, United Kingdom

Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85

Phase 1
Completed
Conditions
Healthy Volunteer
Dry Age-related Macular Degeneration
Interventions
First Posted Date
2022-12-28
Last Posted Date
2023-02-23
Lead Sponsor
RBP4 Pty Ltd
Target Recruit Count
15
Registration Number
NCT05667688
Locations
🇦🇺

Nucleus Network, Melbourne, Australia

This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease

Phase 1
Completed
Conditions
Stargardt Disease
Interventions
First Posted Date
2022-03-04
Last Posted Date
2024-04-12
Lead Sponsor
RBP4 Pty Ltd
Target Recruit Count
13
Registration Number
NCT05266014
Locations
🇦🇺

Sydney Children's Hospitals Network, Westmead, New South Wales, Australia

🇦🇺

Lions Eye Institute, Perth, Western Australia, Australia

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease

Phase 3
Active, not recruiting
Conditions
Stargardt Disease 1
Interventions
Drug: Placebo
First Posted Date
2022-02-17
Last Posted Date
2024-06-07
Lead Sponsor
Belite Bio, Inc
Target Recruit Count
104
Registration Number
NCT05244304
Locations
🇬🇧

Belite Study Site, Southampton, United Kingdom

Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2019-07-02
Last Posted Date
2021-06-18
Lead Sponsor
Belite Bio, Inc
Target Recruit Count
40
Registration Number
NCT04005807
Locations
🇺🇸

PPD Phase I Clinic, Austin, Texas, United States

Safety and Tolerability Study of LBS-008 in Healthy Adult Subjects After Single and Multiple Doses

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: Placebos
First Posted Date
2018-11-08
Last Posted Date
2020-01-07
Lead Sponsor
RBP4 Pty Ltd
Target Recruit Count
71
Registration Number
NCT03735810
Locations
🇦🇺

Linear Clinical Research, Perth, Australia

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy